3-(2,2,2-trimethylhydrazine)propionate has been researched along with Cardiomyopathies in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goncharova, EV; Govorin, AV | 1 |
| Al-Shabanah, OA; Aleisa, AM; Darweesh, AQ; Fatani, AG; Rizwan, L; Sayed-Ahmed, MM | 1 |
2 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Cardiomyopathies
| Article | Year |
|---|---|
[Changes in fatty acids content in blood red cells of patients with iron-deficiency anemia treated with sorbifer and mildronate].
Topics: Anemia, Iron-Deficiency; Cardiomyopathies; Cardiovascular Agents; Drug Therapy, Combination; Erythrocytes; Fatty Acids; Follow-Up Studies; Humans; Methylhydrazines; Middle Aged; Treatment Outcome; Vitamin E; Vitamins | 2008 |
Carnitine deficiency aggravates cyclophosphamide-induced cardiotoxicity in rats.
Topics: Acetyl Coenzyme A; Adenosine Triphosphate; Animals; Antineoplastic Agents, Alkylating; Cardiomyopathies; Carnitine; Creatine Kinase, MB Form; Cyclophosphamide; Disease Models, Animal; L-Lactate Dehydrogenase; Male; Methylhydrazines; Rats; Rats, Wistar; Risk Factors | 2010 |